

**Update: Limited Shipment of ACENOBEL Sustained Release Tablet 500 mg  
for Distal Myopathy with Rimmed Vacuoles–**

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; Managing Director and CEO: Jin Shiomura) announced today regarding the supply outlook of ACENOBEL Sustained Release Tablet 500 mg for distal myopathy with rimmed vacuoles (this “Product”), which is under shipment control since January 2025 as the demand showed to exceed its expectation substantially after the launch in December 2024.

The company is making efforts to set up a new manufacturing facility in order to meet such huge demand, but more time is needed to build a steady supply system.

While the timing of lifting shipment restriction at this point in time is expected to be around November 2027, we will make a timely announcement on the company website (<https://www.nobelpharma.co.jp/>) in case of any changes in the shipping status and/or the lifting schedule. We sincerely apologize to patients in need of this Product and their families, and everyone in relation to this Product for not being able to ensure a stable supply which is the important mission of a pharmaceutical company.

**[Contact Information]**

**<https://www.nobelpharma.co.jp/en/contact/general-form>**

**Etsuro Hayashi, Head of Communications**

**1-17-24 Shinkawa, Chuo-ku, Tokyo 104-0033**

**Tel: 03-6670-3800**